Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 8/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 9/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.46 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | WNK1 | Q9H4A3 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3998489 | 0.90 | KMT2A (0.70) | KMT2AMEN1MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL523815 | 0.90 | MAPT (0.59) | KMT2AMEN1MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL19692621 | 0.90 | KMT2A (0.55) | KMT2AMEN1MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL29387647 | 0.90 | MAPT (0.59) | KMT2AMEN1MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL4000252 | 0.89 | MEN1 (0.56) | KMT2AMEN1MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL29832280 | 0.88 | MAPT (0.53) | KMT2AMEN1MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL31525064 | 0.88 | KMT2A (0.53) | KMT2AMEN1MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL3998455 | 0.87 | MEN1 (0.54) | KMT2AMEN1MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL3997877 | 0.86 | PKM (0.53) | KMT2AMEN1MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL16037790 | 0.86 | KMT2A (0.56) | KMT2AMEN1MAPTSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240376104-A1 | Bcl-2 Inhibitors | BEIGENE LTD. (KY) | 2024-11-14 | — | — | US | disclosed |
| US-12077536-B2 | BCL-2 inhibitors | BEIGENE, LTD. (KY) | 2024-09-03 | — | — | US | disclosed |
| US-20220402915-A1 | BCL-2 INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2022-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402915-A1 | BCL-2 INHIBITORS | BCL2, BCL2L1, BCL2L2 | KMT2A 2464/4885MEN1 3803/4885MAPT 2900/4885 |
| US-12077536-B2 | BCL-2 inhibitors | BCL2, BCL2L1, BCL2L2 | KMT2A 2464/4885MEN1 3803/4885MAPT 2900/4885 |
| US-20240376104-A1 | Bcl-2 Inhibitors | BCL2, BCL2L1, BCL2L2 | KMT2A 2464/4885MEN1 3803/4885MAPT 2900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.